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Abstract: The underlying problem for two of
the three most common patterns of
unexpected hospital deaths (PUHD) is
hypoventilation1. Current methods of postoperative respiratory monitoring give
delayed signals and have a high false
positive rate leading nurses to ignore
alarms. We hypothesize there exists a
combination of low cost sensors which are
capable of providing real time feedback and
alarms regarding obstructive sleep apnea
and ventilatory depression. Such a monitor
would be useful during space travel when
monitoring personnel are limited following
an injury or if astronauts were to be sedated
during extended travel. Methods: Twenty-six
subjects were recruited to participate in a
study of the effects of Propofol and
Remifentanil. Throughout the day, these
patients were exposed to varying levels of
both drugs simultaneously via target
controlled infusions. These patients were
attached to breathing and oxygen monitors
including chest bands, pulse oximeters,
nasal pressure sensors, C02 capnography,
breathing microphones, and thermistors.
The patients were then observed for types
of apnea or ventilatory depression. Results:
The study is currently ongoing however
preliminary analyses of the data indicate
multiple low cost sensors are capable of
detecting breathing as well as obstructive
events and apnea. Conclusion: Using only a
combination of low cost sensors, we can
provide real time respiratory event data to
nurses and practitioners.

INTRODUCTION & BACKGROUND
The underlying problem for two of the three
most common patterns of unexpected
hospital deaths (PUHD) is hypoventilation1.
Type II PUHD (CO2 narcosis) involves a
reduction in respiratory rate and/or tidal
volume, and if supplemental oxygen is
being provided, a pulse oximeter will not
detect the problem until the hypercarbia is
significantly advanced and the patient is
near respiratory arrest. Type III PUHD is
induced by obstructive sleep apnea in the
presence of arousal failure, and is
recognized as a repetitive sequence of
cyclic apneas and self-arousals which
precede the final apnea. A pulse oximeter
alarms with each apneic period and will
likely be interpreted as generating many
false positive alarms.1 The risk of opioidinduced
respiratory
depression
in
postoperative patients is greatest in the first
24 hours after initiation of opioids2, and
opioids are the most commonly used drug
for treating pain in the postoperative
period.3
These problems would be especially
apparent in space travel where monitoring
personnel are limited due to either sedation
of crew members or an injury rendering the
crew short-handed.
Respiratory depression is caused by druginduced inhibition of the breathing control
center of the brain stem. Partial to full
airway obstruction is an anatomic problem
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involving the soft palate, tongue base,
and/or epiglottis, caused by drug-induced
decreases in airway patency and muscle
tone. Sedatives and opioids depress the
response to elevated CO2 (reduced drive to
breathe), worsen arousal, cause airway
obstruction, and change sleep patterns4-8
In the postoperative period, most adverse
respiratory events occur during the first 24
hours of opioid administration.2 During this
period,
pulse
oximeter
monitoring,
supplemental oxygen, incentive spirometry,
and intermittent nursing observation are the
primary interventions used to fend off
adverse respiratory events. For inpatient
monitoring, pulse oximetry is often
inadequate. On a busy hospital floor, it is
difficult to respond to multiple remote
advisory pulse oximetry alarms. Pulse
oximeter alarms are ignored because they
have a high false-positive alarm rate due to
movement artifact and displacement.9,10
Pulse
oximetry
primarily
monitors
oxygenation instead of ventilation; the SpO2
signal is a delayed indicator for apnea or
hypopnea, particularly when supplemental
oxygen is given. By the time the pulse
oximeter alarms, an apneic patient is
already in danger of hypoxia, brain injury
and death.
Existing
technologies
may
improve
monitoring of adverse respiratory events in
this setting, but are either costly or difficult
to implement. For example, monitoring
ventilation with capnography is expensive
and it can be problematic to sample the
exhaled gas with a face mask or nasal
cannula
in
non-intubated
patients.11
Acoustic respiratory rate monitoring may be
able to detect airway obstruction, but it is
costly and may not have sufficient sensitivity
to reliably detect apnea events.12 We
suggest that there is an urgent need for a
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low cost, reliable respiratory depression
monitoring technique that can be integrated
with the signals from the pulse oximeter to
give additional physiologic information about
a patient’s sufficiency of both ventilation and
oxygenation.
Currently, we are exploring the value of
integrating the information from a set of lowcost physiologic monitors that can be
adapted to monitoring patients in a hospital
floor setting. In addition to the red and
infrared component signals that comprise
the pulse oximeter plethysmography
waveform,
we
intend
to
integrate
information from motion sensors on the
finger, head, abdomen, chest wall and bed,
temperature, pressure and carbon dioxide
sensors embedded in a nasal cannula and
acoustic respiratory rate via a microphone
on the throat. We will determine from the
tested set the fewest number and least
costly types of sensors that can be used to
accurately identify and quantify ventilatory
depression and airway obstruction, provide
reliable measures of oxygenation AND
ventilation, provide specific alarms, and
avoid artifact. We will evaluate this multisensor set for volunteers who receive
medications
to
produce
ventilatory
depression and/or partial to complete airway
obstruction.
Our team previously characterized various
effects of sedatives combined with opioids
using drug interaction models. Specifically,
we characterized the interaction of Propofol
and Remifentanil on metrics of airway
obstruction and intolerable ventilatory
depression in volunteers.8 We defined
intolerable ventilatory depression as a
respiratory rate less than 4 breaths per
minute and airway compromise as either
partial (tidal volume less than 3 mL/kg in the
presence of a respiratory effort) or complete
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obstruction. Respiratory compromise was
defined as either intolerable ventilatory
depression or airway obstruction or both.
Using this model, predictions of respiratory
compromise (0 to 100%) can be made for
various dosing schemes of Propofol and
remifentanil.8 (Figure 1). In general, dosing
schemes that led to high concentration of
Propofol were more likely to produce airway
obstruction
and
higher
doses
of
Remifentanil were more likely to produce
intolerable ventilatory depression.
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Figure 1: A: Dose of a drug, first as a bolus,
then as a continuous infusion. B: effect site
concentration (Ce) Corresponding to the
given dose and C: Observed effect
(sedation) for a single administered drug.
Time points 1-5 correspond to a likelihood of
effect in D: Effect and corresponding drug
concentrations
resulting
in
stated
probabilities for respiratory compromise.

METHODS
A 20 gauge venous catheter was placed in
an antecubital vein under local anesthesia
(0.2 mL of 0.5% lidocaine) for the purpose
of hydration and drug administration. The
IV site was similar in all subjects. A
maintenance infusion of 0.9% sodium
chloride was administered at 1 ml/kg/hour
throughout the study. Continuous infusions
of Remifentanil and Propofol was infused
into this peripheral IV.
Subjects were instrumented with a
noninvasive blood pressure cuff, ECG
leads, pulse oximeter(s), motion sensors,
respiratory inductance plethysmography
"chest bands", capnography nasal cannula,
nasal gas pressure sensor, nasal thermistor
and an acoustic respiratory rate sensor.
These or similar monitors were placed to
measure respiratory rate, tidal volume, endtidal CO2, SpO2, blood pressure, body
motion and heart rate. Chest and abdominal
wall excursion were measured with the
attached motion sensors and the respiratory
inductance
plethysmography
bands.
Changes in respiration pattern were
displayed as real-time changes in CO2
waveforms. A processed EEG monitor
and/or a cerebral oximeter were optionally
placed to record data for later analysis. A
motion sensor was also placed on the bed.
These devices were operational during the
entire study day. Data from devices was
electronically captured and recorded for
later analysis. Continuous variables such as
motion
waveforms,
pulse
oximetry
waveform, capnogram, and nasal airway
pressure were digitized during data
collection periods at 50-1000Hz during data
collection periods at each target effect site
concentration pair. Discrete variables were
recorded every 5 seconds or as soon as
data were available during data collection
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periods. Examples of discrete variables
include heart rate, SpO2, PetCO2, systolic
blood pressure, diastolic blood pressure and
respiratory rate. The tidal volume was
occasionally measured with a differential
pressure flow sensor attached to an
anesthesia mask or mouthpiece in order to
calibrate
the
respiratory
inductance
plethysmography bands.
Each subject received Propofol and
Remifentanil. Similar to previously collected
data from our volunteer laboratory (Kern et
al, 2004), each drug was administered using
a
computer
controlled
(Stanpump14)
continuous infusion pump (Pump 22;
Harvard Apparatus, Limited, Holliston, MA)
to achieve selected target effect site
concentrations.
The
effect
site
concentration
refers
to
the
drug
concentration at the pharmacologic site of
action. Pharmacokinetic
parameters
15
published by Minto et al. and Schnider et
al.16 was used for Remifentanil and Propofol
respectively.
We administered Propofol and Remifentanil
pairs in a dose escalation scheme with
small steps in order to creep up to the
desired target effects of respiratory
depression, airway obstruction and both
effects while avoiding overshoot. To
accomplish this, the Propofol was dosed in
a range of 0.75 - 4 mcg/mL in dose
escalation steps of approximately 0.5
mcg/mL. Remifentanil was dosed in a range
of 0.75 to 4.0 ng/mL in escalation steps of
approximately 0.25-0.5 ng/mL. If overshoot
was observed for a given target effect site
concentration pair, the target effect site
concentrations
were
lowered
so
assessments could be made during the
target effects of respiratory depression or
airway obstruction or both. Once the drug

concentration pair was identified which
resulted in the target effects for a given
subject, the steady state drug dose was
maintained for a period of data collection.
To begin our analysis, we wanted to
compare how well clinical apnea definitions
correlated with minute volume data
collected from our calibrated chest bands. A
small literature search was performed for
apnea definitions. Our data was plotted in a
histogram according to these definitions and
then plotted against minute volume. The
data used in this comparison was primarily
collected during low Propofol dosing
schemes as we are interested in viewing the
effectiveness of central apnea definitions.
Our next goal was to visualize the
effectiveness in apnea detection of different
cranial-centric monitors with respect to the
clinical gold standard of Capnography
monitoring. Data was aligned temporally in
Matlab. Per the previous analysis, we
defined apnea as a period of at least 15
seconds during which no breath was
detected. Because of sample tube delay,
the CO2 signal was shifted by 8 seconds
before comparison to the other signals.
Breath detection for the CO2 signal was
done using the algorithm integrated into the
capnometer (LoFlo, Philips, Wallingford
CT). Breath detection for the nasal pressure
and thermistor signals was performed using
an algorithm we developed based on signal
excursions above and below a baseline
level.
RESULTS
A preliminary analysis of the data has
revealed high correlation between certain
respiratory monitors and specific breathing
related ‘states’.
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These breathing states are ‘normal’
breathing, complete airway obstruction
(obstructive sleep apnea), partial airway
obstruction (partial obstructive sleep apnea
or snoring), and ventilatory depression (nonobstructive sleep apnea) characterized by a
breathing rate of less than four breaths per
minute. The figure below illustrates the
some of the primary complex breathing
patterns that we are interested in
monitoring. Ventilatory depression was not
included in the figure as it appears in the
form of intermittent ‘normal’ breathing with
occasionally reduced volume.
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From this data we can already see multiple
breathing patterns once we combine signals
such as chest or abdomen excursion
(ventilatory effort) and nasal pressure,
expired C02, or thermistor readings
(ventilatory success). In column A, we see
what we would expect for each of these
signals under normal breathing conditions;
The chest and abdomen are in phase with
each other, the biphasic nasal pressure
signal is synced with ventilatory effort, and
the expired C02 increases at expiration.
Column B of figure 2 illustrates how these
signals change during airway obstruction;
Chest and abdomen bands are out of phase

Figure 2: Electronic signals collected during different breathing related ‘states’. The signals
shown from top to bottom are: Chest band, abdomen band, nasal pressure, expired co2,
and thermistor. The columns are one breath samples from the breathing states listed at the
top of the figure.
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with each other (paradoxical) while
measures of ventilatory success are zeroed.
Column C shows partial airway obstruction;
the abdomen band becomes biphasic and
only syncs with the chest during the latter
half of the breath attempt where the
obstruction was partially cleared. The lower
magnitude nasal pressure is one indicator of
the patient’s difficulty passing air.
Upon review of the literature, we found
conflicting opinions regarding the definition of
apnea. Time since last breath is the most
common criteria for an apnea alarm. Scientific
studies have used anywhere from 10-30
seconds in between breaths as the definition of
apnea while clinical monitors can be
programmed to detect lapses of 10-60 seconds
in breathing. 9404 interbreath intervals were
placed on a histogram shown in figure 3. The
histogram follows a Gaussian distribution with
mu=9.58 and lambda=14.10. In the histogram,
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33% of the data lies above the 10 second cutoff.
There appears to be some correlation between
minute volume and interbreath interval,
however there is an extremely large deviation
of minute volumes as indicated by the green
error bars. Error bars are bounded by two
standard deviations from the mean.
Next we compared the effectiveness in
apnea detection of the cranial-centric
monitors shown in figure 1 (nasal pressure,
thermistor) to the clinical Phillips monitor
Capnography based detection. The results
of this analysis are provided in table 1 and
table 2. Table 1 depicts the comparison
when the Propofol dose was low (<1
mcg/mL). Table 2 depicts the comparison
when Remifentanil dose was low (<1
ng/mL). Data is shown as normalized
percentages. True positive is define as an
apnea flag present in both signal 1 and
signal 2. True negative is defined no apnea

Figure 3: Histogram of 9404 interbreath intervals. The histogram follows a Gaussian
distribution with mu=9.58 and lambda=14.10. Minute volume is plotted on the second Yaxis. Some correlation exists but the variance is large.
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flag in either signal 1 or 2. False positive is
defined as an apnea flag in signal 1 with no
apnea flag in signal 2. False negative is
defined as no apnea flag in signal 1 and an
apnea flag in signal 2.
CONCLUSION
A low cost, accurate, and minimally sized
respiratory monitor would be useful during
space travel when personnel are limited
following an injury/emergency procedure or
if astronauts were to be sedated during
extended voyages.
Overall, preliminary analysis of the signals
has been successful in proving that within
individual patients, low cost signals exhibit
discernible patterns during obstructive
apnea, partial airway obstruction, and
ventilatory depression.
Our analysis of apnea definitions and

indicate that there is a need for a more
robust respiratory monitor.
We’ve shown that there is at least moderate
correlation between our cranial-centric
sensors and the clinical standard of
Capnography. Discrepancies in detection
rate between these sensors can be
attributed to a number of factors. To begin
with, neither algorithm is perfect. While the
overall number of breaths and apneas
detected by each signal was similar, an
incorrect breath assessment may result in
an incorrect apnea flag. Capnography
monitoring is especially prone to false
positive breath detections when breathing
rate is low—as in this study. Additionally,
the comparison is being made between two
sensors placed on the face and a side
stream Capnometer. While attempts were
made to temporally align the signal, the time
delay is the Capnometer is dependent on

Signal 1

Signal 2

True
Positive

True
Negative

False
Positive

False
Negative

Nasal Pressure

Capnography

0.13

0.66

0.15

0.07

Thermistor

Capnography

0.08

0.73

0.07

0.12

Nasal Pressure

Thermistor

0.05

0.78

0.10

0.08

Table 1: Comparison of apnea detection in cranial centric monitors. This comparison was made
during low Propofol dosing schemes (Propofol <1 mcg/mL).
Signal 1

Signal 2

True
Positive

True
Negative

False
Positive

False
Negative

Nasal Pressure

Capnography

0.05

0.78

0.14

0.03

Thermistor

Capnography

0.02

0.88

0.04

0.06

Nasal Pressure

Thermistor

0.03

0.77

0.03

0.16

correlation

with

minute

volumes

also

the rate of flow through the nose. Finally,

Table 2: Comparison of apnea detection in cranial centric monitors. This comparison was
made during low Remifentanil dosing schemes (Remifentanil <1 mcg/mL).

2014 Rocky Mountain Space Grant Consortium

the measured signals are fundamentally
different. Capnometry measures gas
concentration but is not dependent on
volume or rate of gas flow. Nasal pressure
and thermistor are sensitive to gas flow and
volume and position of the cannula prongs
in the nares.
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